Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07222059 | Phase 3 Single Arm, Open Study on vYF in Adults | PHASE3 | COMPLETED | 254 | — | — | Oct 23, 2025 | Dec 25, 2025 | Feb 3, 2026 | 4 | Japan |
Seroconversion rates will be assessed using a YF MN assay Seroconversion is defined as a 4-fold increase in neutralizing Ab (NAb) titers as compared to the pre-vaccination value (Day 01)
| Arm | Type | Description |
|---|---|---|
| vYF | EXPERIMENTAL | One single dose of vYF will be administered subcutaneously at the 1st visit |
| Name | Type | Description |
|---|---|---|
| Yellow fever vaccine (live) | BIOLOGICAL | Pharmaceutical form:Powder and diluent for suspension for injection-Route of administration:Subcutaneous |
Inclusion Criteria: * Aged from 18 years on the day of inclusion\* \* "From 18 years" means from the day of the 18th birthday * Participants who are healthy as determined by medical evaluation including medical history and physical examination. * Able to attend all scheduled visits and to comply...